Novel Therapy for CKD Anemia Advances
PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.
Kidney Week 2011 Anemia
IV Iron Drug Shows Advantages in Head-to-Head Trial
PHILADELPHIA—Ferumoxytol has an efficacy comparable to iron sucrose in treating iron deficiency anemia in patients with chronic kidney disease (CKD), but is associated with lower adverse event (AE) rates, according to the findings a head-to-head comparison of the two formulations presented at Kidney Week 2011.
Once-Monthly ESA Maintains Stable Hemoglobin Levels
PHILADELPHIA—Once-monthly peginesatide, an investigational peptide-based erythropoiesis stimulating agent (ESA), is similar to epoetin administrated one to three times weekly in maintaining mean hemoglobin levels in the 10-12 g/dL range in hemodialysis patients with anemia, according to study findings presented at Kidney Week 2011.
EPO Use Declining After Bundling Introduced
PHILADELPHIA—Epoetin alfa (EPO) use has decreased and intravenous (IV) iron use has increased significantly in private dialysis units since the introduction of the Medicare bundling rule for end-stage renal disease services, data presented at Kidney Week 2011 suggest.
IV Iron Use for Anemia Rising, ESA Use Falling
PHILADELPHIA—The use of intravenous (IV) iron for managing anemia in hemodialysis (HD) patients has increased steadily from 2002 to 2008, even after declines in the use of erythropoiesis stimulating agents (ESAs), as reported from data presented at Kidney Week 2011.
HD-Related Damage Not a Factor in CKD-Related Anemia
PHILADELPHIA—Mechanical damage to red blood cells (RBC) from hemodialysis (HD) does not contribute to anemia in HD patients, according to study findings presented at Kidney Week 2011.
Response to ESAs Predicts ESRD Risk
PHILADELPHIA—Patients with chronic kidney disease (CKD) who have a low response to erythropoiesis-stimulating agents (ESAs) are at increased risk of progressing to end-stage renal disease (ESRD), investigators reported at Kidney Week 2011.
ESA Resistance Increases Death Risk More in HD than PD Patients
PHILADELPHIA—Most patients on peritoneal dialysis (PD) receive substantially lower doses of erythropoiesis stimulating agents (ESAs) for the same achieved hemoglobin levels compared with patients on hemodialysis (HD), investigators reported at Kidney Week 2011.
BP Rises with ESAs Not Relate to Vasoconstriction
PHILADELPHIA—New study findings may narrow down the possible causes of increased blood pressure (BP) result from the use of erythropoiesis stimulating agents (ESAs) to correct renal anemia, according to a report presented at Kidney Week 2011.
Diabetes Boosts CKD Patients’ Comorbidities
PHILADELPHIA—Patients with chronic kidney disease (CKD) who also have diabetes have significantly higher rates of anemia, cardiovascular disease, and other comorbidities compared with nondiabetic CKD patients, study findings presented at Kidney Week 2011 show.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...